USA - NASDAQ:YTEN - US98585K8541 - Common Stock
The current stock price of YTEN is 2.88 USD. In the past month the price decreased by -56.91%. In the past year, price decreased by -96.01%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 382.94B | ||
| AMGN | AMGEN INC | 14.63 | 172.20B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.02 | 106.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.31 | 68.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 852.08 | 56.96B | ||
| ARGX | ARGENX SE - ADR | 62.07 | 51.25B | ||
| INSM | INSMED INC | N/A | 39.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.19 | 35.30B | ||
| NTRA | NATERA INC | N/A | 27.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.86B | ||
| BIIB | BIOGEN INC | 9.17 | 22.49B |
Yield10 Bioscience, Inc. is an agricultural bioscience company, which engages in the development of oilseed Camelina sativa as a platform crop for large scale production of low carbon sustainable seed products. The company is headquartered in Woburn, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2006-11-10. The firm is using its differentiated trait gene discovery platform, the TraitFactory, to develop improved Camelina varieties for the production of seed products, and to discover high value genetic traits for the agriculture and food industries. The seed products include Camelina oil for use as a low carbon biofuel feedstock, Omega-3 oils for nutrition and PHA Bioplastics for biodegradable zero-waste packaging solutions. The company is developing the oilseed Camelina sativa (Camelina) as a platform crop for large scale production of low carbon sustainable seed products to address petroleum replacement markets, food and nutrition markets, and animal feed markets. The company is engaged in the development of elite Camelina germplasm exhibiting herbicide tolerance, disease resistance and other traits. The firm's development pipeline falls into three categories: input traits, performance traits and new seed product traits.
YIELD10 BIOSCIENCE INC
19 Presidential Way Ste 201
Woburn MASSACHUSETTS 01801 US
CEO: Oliver P. Peoples
Employees: 30
Phone: 16175831700
Yield10 Bioscience, Inc. is an agricultural bioscience company, which engages in the development of oilseed Camelina sativa as a platform crop for large scale production of low carbon sustainable seed products. The company is headquartered in Woburn, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2006-11-10. The firm is using its differentiated trait gene discovery platform, the TraitFactory, to develop improved Camelina varieties for the production of seed products, and to discover high value genetic traits for the agriculture and food industries. The seed products include Camelina oil for use as a low carbon biofuel feedstock, Omega-3 oils for nutrition and PHA Bioplastics for biodegradable zero-waste packaging solutions. The company is developing the oilseed Camelina sativa (Camelina) as a platform crop for large scale production of low carbon sustainable seed products to address petroleum replacement markets, food and nutrition markets, and animal feed markets. The company is engaged in the development of elite Camelina germplasm exhibiting herbicide tolerance, disease resistance and other traits. The firm's development pipeline falls into three categories: input traits, performance traits and new seed product traits.
The current stock price of YTEN is 2.88 USD. The price decreased by -45.25% in the last trading session.
YTEN does not pay a dividend.
YTEN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
YIELD10 BIOSCIENCE INC (YTEN) has a market capitalization of 44.35M USD. This makes YTEN a Nano Cap stock.
You can find the ownership structure of YIELD10 BIOSCIENCE INC (YTEN) on the Ownership tab.
ChartMill assigns a fundamental rating of 1 / 10 to YTEN. YTEN has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months YTEN reported a non-GAAP Earnings per Share(EPS) of -32.44. The EPS decreased by -1075.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -370% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
7 analysts have analysed YTEN and the average price target is 12.24 USD. This implies a price increase of 325% is expected in the next year compared to the current price of 2.88.
For the next year, analysts expect an EPS growth of 97.63% and a revenue growth 2712.5% for YTEN